Non-Hodgkin's lymphomas, version 2.2014

Andrew D. Zelenetz; Leo I. Gordon; William G. Wierda; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; Naresh Bellam; John C. Byrd; Myron S. Czuczman; Luis E. Fayad; Richard I. Fisher; Martha J. Glenn; Nancy Lee Harris; Richard T. Hoppe; Steven M. Horwitz; Christopher R. Kelsey; Youn H. Kim; Susan Krivacic; Ann S. LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Lubomir Sokol; Lode J. Swinnen; Christina Tsien; Julie M. Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar

doi:10.6004/jnccn.2014.0086

Non-Hodgkin's lymphomas, version 2.2014

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasceAuayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar

Leukemia

Research output: Contribution to journal › Review article › peer-review

58 Scopus citations

Abstract

Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

Original language	English (US)
Pages (from-to)	916-946
Number of pages	31
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	12
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2014.0086
State	Published - Jun 1 2014

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2014.0086

Cite this

Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, M. J., Harris, N. L., Hoppe, R. T., Horwitz, S. M., Kelsey, C. R., Kim, Y. H., Krivacic, S., ... Sundar, H. (2014). Non-Hodgkin's lymphomas, version 2.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(6), 916-946. https://doi.org/10.6004/jnccn.2014.0086

Zelenetz, AD, Gordon, LI, Wierda, WG, Abramson, JS, Advani, RH, Andreadis, CB, Bartlett, N, Bellam, N, Byrd, JC, Czuczman, MS, Fayad, LE, Fisher, RI, Glenn, MJ, Harris, NL, Hoppe, RT, Horwitz, SM, Kelsey, CR, Kim, YH, Krivacic, S, LaCasce, AS, Nademanee, A, Porcu, P, Press, O, Rabinovitch, R, Reddy, N, Reid, E, Sokol, L, Swinnen, LJ, Tsien, C, Vose, JM, Yahalom, J, Zafar, N, Dwyer, M & Sundar, H 2014, 'Non-Hodgkin's lymphomas, version 2.2014', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 6, pp. 916-946. https://doi.org/10.6004/jnccn.2014.0086

@article{a978ca0badc444579b772888955f7f25,

title = "Non-Hodgkin's lymphomas, version 2.2014",

abstract = "Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.",

author = "Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Wierda, {William G.} and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Andreadis, {C. Babis} and Nancy Bartlett and Naresh Bellam and Byrd, {John C.} and Czuczman, {Myron S.} and Fayad, {Luis E.} and Fisher, {Richard I.} and Glenn, {Martha J.} and Harris, {Nancy Lee} and Hoppe, {Richard T.} and Horwitz, {Steven M.} and Kelsey, {Christopher R.} and Kim, {Youn H.} and Susan Krivacic and LaCasce, {Ann S.} and Auayporn Nademanee and Pierluigi Porcu and Oliver Press and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Lubomir Sokol and Swinnen, {Lode J.} and Christina Tsien and Vose, {Julie M.} and Joachim Yahalom and Nadeem Zafar and Mary Dwyer and Hema Sundar",

year = "2014",

month = jun,

day = "1",

doi = "10.6004/jnccn.2014.0086",

language = "English (US)",

volume = "12",

pages = "916--946",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "6",

}

TY - JOUR

T1 - Non-Hodgkin's lymphomas, version 2.2014

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Wierda, William G.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Andreadis, C. Babis

AU - Bartlett, Nancy

AU - Bellam, Naresh

AU - Byrd, John C.

AU - Czuczman, Myron S.

AU - Fayad, Luis E.

AU - Fisher, Richard I.

AU - Glenn, Martha J.

AU - Harris, Nancy Lee

AU - Hoppe, Richard T.

AU - Horwitz, Steven M.

AU - Kelsey, Christopher R.

AU - Kim, Youn H.

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Nademanee, Auayporn

AU - Porcu, Pierluigi

AU - Press, Oliver

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Sokol, Lubomir

AU - Swinnen, Lode J.

AU - Tsien, Christina

AU - Vose, Julie M.

AU - Yahalom, Joachim

AU - Zafar, Nadeem

AU - Dwyer, Mary

AU - Sundar, Hema

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

AB - Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

UR - http://www.scopus.com/inward/record.url?scp=84902504593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902504593&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0086

DO - 10.6004/jnccn.2014.0086

M3 - Review article

C2 - 24925202

AN - SCOPUS:84902504593

SN - 1540-1405

VL - 12

SP - 916

EP - 946

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

Non-Hodgkin's lymphomas, version 2.2014

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this